|
0
Votes
vote
Early Phase II clinical trial for RK-023 to treat androgenetic alopeciaR-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness). ... |

